HR-positive, HER2-negative breast carcinoma
Conditions
Interventions
The observation group of breast malignant tumors with HR positive and HER-2 negative:None
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who visited the hospital from January 1, 2026 to December 31, 2028; 1. Patients with HR+/HER2- advanced breast cancer who have not received or have received at most one line of CDK4/6i treatment; 2. Patients for whom the investigator plans to administer lorlatinib treatment; 3. ECOG PS (Eastern Cooperative Oncology Group Performance Status): 0-2 points;
Exclusion criteria
Exclusion criteria: 1.Patients with known active brain metastases; 2.Patients with advanced, symptomatic visceral metastases at risk of developing life-threatening complications in the short term; 3.Patients with significant comorbidities. 4.Patients deemed ineligible for enrollment by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The progression-free survival period utilized by Lorus for patients with advanced breast cancer of HR+/HER2- type;The progression-free survival period utilized by Lorusi for patients with advanced breast cancer of HR+/HER2- type in the second line treatment stage; | — |
Secondary
| Measure | Time frame |
|---|---|
| Therapeutic model;The safety of patients receiving treatment at Roselli Hospital; | — |
Countries
China
Contacts
Public ContactXiaojia Wang
Zhejiang Cancer Hospital
Outcome results
None listed